本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Spectrum Pharmaceuticals

1.03
0.0000
成交量:- -
成交额:602.88万
市值:2.10亿
市盈率:-3.03
高:1.03
开:1.03
低:1.03
收:1.03
数据加载中...
2023/09/27

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/09/26

员工持股计划

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
2023/08/01

交易所摘牌声明

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
2023/08/01

重要事件披露

Form 8-K - Current report
2023/07/27

重要事件披露

Form 8-K - Current report
2023/06/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/05/17

重要事件披露

Form 8-K - Current report
2023/05/11

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2023/05/09

重要事件披露

8-K - Current report
2023/05/09

企业合并公告

425 - Prospectuses and communications, business combinations
2023/05/01

[修订]年度报告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/05/01

重要事件披露

8-K - Current report
2023/04/25

企业合并公告

425 - Prospectuses and communications, business combinations
2023/04/25

重要事件披露

8-K - Current report